TheraVet Unveils Its Development Strategy to Address the Equine Market By Investing.com

• Positioning focused on competition horses, a highly dynamic market correlated with the more than $400 billion sport betting market
• Answer to the main indications affecting competition horses provided by the BIOCERA-VET ® and VISCO-VET ® ranges
• New therapeutic solutions dedicated to equine competition to be launched by 2027

GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News:

TheraVet (ISIN: BE0974387194 – Ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the deployment of its range of solutions in the highly dynamic competition horse segment.

Following the launch in March 2024 of two BIOCERA-VET ® references specially adapted to equine applications, TheraVet now intends to position itself as the reference in the osteoarticular disease treatments in horses dedicated to competition, a worldwide population of 12 million animals. Equine competition is an important part of the global betting industry, a market valued at $402 billion in 2022, which is expected to grow by ~8.9% a year between now and 20301, topping the $790 billion.

The BIOCERA-VET ® Equine range and the VISCO-VET ® program currently under development ensure to TheraVet a unique position in the treatment of the main indications affecting these animals. For example, thanks to its properties required for cementoplasty (high injectability, easy handling, high radiopacity, strong cohesiveness and fast self-setting), BIOCERA-VET ® Equine enables the minimally invasive treatment of subchondral bone cysts, whose presence has a negative impact on the auction price by causing lameness and poor performance.

With the support of specialist equine orthopedic surgeons, TheraVet’s solutions have so far been used to treat 19 cases of subchondral bone cysts and maxillofacial and dental problems. These ongoing clinical evaluations are designed to reinforce BIOCERA-VET ®’s position as the preferred, and in fine, first-line treatment option for equine bone cysts, osteoarticular diseases and dental problems affecting competition horses.

TheraVet plans to enrich its range of products dedicated to competition horses with several launches between now and 2027, including BIOCERA-VET ® OSTEO, with its enhanced osteo-inductive properties, NUTRA-VET ®, a range of high-performance nutraceuticals, and VISCO-VET ® Equine, an equine version of the visco-regenerating gel…